GlassScriptPhysician profile
Brian S Phelps
NPI 1689866576
$13,595.08
in general payments reported to CMS, 2019-2025
23 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $8,330 · 2021: $446 · 2022: $269 · 2023: $876 · 2024: $2,314 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400 · Honoraria: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,400.49 |
| Honoraria | $1,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $6,653.40 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $2,312.38 | 2019-2024 | Iluvien, Yutiq |
| Allergan, INC. | $1,914.96 | 2019-2021 | |
| Genentech USA, INC. | $486.87 | 2019-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $437.72 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $429.42 | 2024-2025 | Yutiq, Iluvien, Purified Cortrophin Gel |
| Abbvie INC. | $235.01 | 2022-2025 | |
| Dutch Ophthalmic, USA | $147.54 | 2024 | Eva, Combined Machine, Tissueblue |
| Regeneron Pharmaceuticals, INC. | $142.70 | 2024 | Eylea Hd |
| Biogen, INC. | $132.52 | 2023 | |
| Eyepoint US, INC. | $119.14 | 2021-2023 | |
| Astellas Pharma US INC | $90.52 | 2023-2025 | Izervay |
| Genentech, INC. | $69.33 | 2019 | |
| Aerie Pharmaceuticals, INC. | $67.13 | 2021 | |
| Coherus Oncology, INC. | $65.94 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $59.48 | 2020 | |
| Optos, INC. | $55.73 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $40.96 | 2022-2024 | Xipere |
| Alcon Vision LLC | $39.08 | 2020-2025 | Simbrinza |
| Ocular Therapeutix, INC. | $36.37 | 2021 | |
| Boston Scientific Corporation | $31.50 | 2024 | Wavewriter Alpha Prime 16 |
| Astellas Pharma Global Development | $13.93 | 2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Phelps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.